Latest News - Clinical Trials

Thursday, August 23, 2018

FDA Grants Marketing Approval for Brainsway Ltd’s Brain Stimulation Device for OCD

The US Food and Drug Administration (FDA)granted marketing approval of August 17 for Brainsway Ltd’s deep intracranial magnetic stimulation (dTMS) system for the treatment of obsessive-compulsiv…

Read the full story

Thursday, August 02, 2018

Heading the Ball in Soccer May Affect Women's and Men's Brains Differently

In a new study from researchers at the Albert Einstein College of Medicine (Radiology. 2018;July 31), imaging findings suggest that heading the ball in soccer may affect women's brains differently…

Read the full story

Wednesday, June 20, 2018

Impulse Control Disorders More Common in People Who Take Dopamine Agonists

A French study which followed 411 people for an average of three years who had been diagnosed with Parkinson’s disease (PD) within 5 years, has reported an increase in impulse control disorders …

Read the full story

Wednesday, June 13, 2018

Risk for Parkinson’s Disease May Be Linked to an Earlier Diagnosis of Diabetes

A study from England published online in Neurology on June 13 suggests that people with type 2 diabetes may have an increased risk of developing Parkinson’s disease (PD) later in …

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Tuesday, April 24, 2018

First Results in Humans for Antisense Oligonucleotide Treatment of Patients with Huntington’s Disease

At the American Academy of Neurology meeting in Los Angeles, researchers Sarah Tabrizi, Blair Leavitt, Holly Kordasiewicz, and others presented their results using antisense oligonucleotides (ASO) (IO…

Read the full story

Thursday, March 22, 2018

Phase 3 Clinical Trial Shows Siponimod Significantly Improved Outcomes in Patients With Secondary Progressive Multiple Sclerosis

Results from the phase 3 clinical trial, EXPAND, studying oral, once-daily siponimod (Novartis; East Hanover, NJ) for treatment of secondary progressive multiple sclerosis (SPMS) were published today …

Read the full story

Tuesday, March 20, 2018

Global Alzheimer's Platform Foundation Partners with Lyft to Provide Free Transportation to Research Sites for Clinical Trial Participants

In partnership with Lyft (San Francisco, CA), the Global Alzheimer's Platform Foundation (GAP) (Washington, DC) is beginning a pilot program to provide free transportation to and from research sit…

Read the full story

Wednesday, March 14, 2018

Results From Cannabidiol Dose-Ranging Safety Trial for Treating Patients With Dravet Syndrome

Previous randomized controlled trials have suggested that orally administered cannabidiol (CBD) is effective as an add-on to existing antiepileptic drugs (AEDs) for the treatment of convulsive seizure…

Read the full story

Tuesday, March 06, 2018

First Patient Enrolled in Phase 3 Clinical Trial of Rimegepant for Acute Migraine Treatment

Biohaven Pharmaceutical (New Haven, CT) announced today the first patient enrollment in their phase 3 clinical trial of rimegepant (Zydis) for the acute treatment of migraine.  Zydis is an orally…

Read the full story

Wednesday, February 07, 2018

Phase 3 Trial of P2B001 for Early-Stage Parkinson's Disease Begins With First Patients Receiving First Dose

The drug P2B001(Pharma Two B) is a combination product of pramipexole 0.6mg and rasagiline 0.75 mg given together once daily. Rasagiline is a monoamine oxidase inhibitor used to treat Parkinson&r…

Read the full story

Tuesday, February 06, 2018

Food and Drug Administration Grants Breakthrough Therapy Designation for ZX008 for Treatment of Dravet Syndrome

Low-dose fenfluramine (ZX008, Zogenix) is classified as an orphan drug for the treatment of two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. Positive results from the first piv…

Read the full story

Thursday, February 01, 2018

Post Hoc Clinical Trials Data for Cladribine, An Investigational Oral Multiple Sclerosis Treatment

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced that new clinical trial data is being released during the Americas Committee for Treatment and Research in Multi…

Read the full story

Thursday, January 25, 2018

First Prospective Registry Shows Efficacy of Neuromodulation of the Sphenopalatine Ganglion for Treating Cluster Headache

On January 25, 2018, The Journal of Headache and Pain published one-year results from an open-label registry trial, Pathway R-1, evaluating the efficacy of sphenopalatine-ganglion stimulation (SPGs) (…

Read the full story

Monday, January 08, 2018

PROMISE Phase 3 Trial for Chronic Migraine Prevention Meets Primary and All Key Secondary Endpoints; Shows Reduction in Migraine Risk

January 8, 2018--Alder Biopharmaceutical reported that their injectable calcitonin-gene-related peptide (CGRP)-inhibitor eptinezumab, in phase 3 clinical trials, reduced monthly migraine days by 50% o…

Read the full story
Load More